{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-015582","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2023-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.152052+00:00","generated_at":"2026-06-10T22:07:52.110180+00:00","sec_items":["2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Coherus completes acquisition of Surface Oncology for ~$66.9M in stock and CVRs","bullets":["Coherus issued 0.1960 shares per Surface share for total consideration of ~$66.9M ($40M + 26.9M net cash).","Surface shareholders received CVRs for 70% of milestone/royalty value from Novartis and GSK programs, and 25-50% of future ex-US licensing payments for CHS-114 and casdozokitug.","Acquired pipeline: toripalimab (anti-PD-1 under BLA review), casdozokitug (IL-27 antibody Phase 2), CHS-114 (CCR8 antibody Phase 1/2), CHS-006 (TIGIT antibody Phase 1/2).","Surface common stock delisted from Nasdaq Capital Market effective September 8, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-015582","json":"https://secwatch.observer/filing/0001558370-23-015582.json","markdown":"https://secwatch.observer/filing/0001558370-23-015582.md","text":"https://secwatch.observer/filing/0001558370-23-015582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023015582/0001558370-23-015582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023015582/chrs-20230908x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:07:52.110180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1067fe1c1ce0ff8e5fa0e602993dc6c27fb8c5d8","claim":"Coherus Oncology, Inc. completed an acquisition involving Surface Oncology, Inc. for approximately $66.9 million (closed 2023-09-08).","evidence_excerpt":"Surface employee equity awards (which exchange ratio was calculated based on a $5.2831 per share price of Coherus common stock) for a total value equal to approximately $66.9 million, the sum of $40 million plus Surface’s net cash at closing of the transaction of $26.9 million. Surface shareholders also received contingent value rights (CVRs) for 70% of","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023015582/0001558370-23-015582-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Surface Oncology, Inc."},{"label":"Consideration","value":"approximately $66.9 million"},{"label":"Closing","value":"2023-09-08"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}